DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

Table 2 P value among methylated genes and EGFR mutation

	sFRP1	sFRP2	sFRP5	DKK3	WIF-1	APC	CDH-1	EGFR mutation
sFRP1	NA	0.004	0.005	0.008	0.02	<0.0001	0.266	0.005
sFRP2	0.004	NA	<0.0001	<0.0001	0.007	<0.0001	<0.0001	0.854
sFRP5	0.005	<0.0001	NA	<0.0001	<0.0001	0.06	<0.0001	0.011
DKK3	0.008	<0.0001	<0.0001	NA	0.0001	0.006	<0.0001	0.489
WIF-1	0.02	0.007	<0.0001	<0.0001	NA	0.03	0.02	0.094
APC	<0.0001	<0.0001	0.06	0.006	0.03	NA	0.126	0.546
CDH-1	0.266	<0.0001	<0.0001	<0.0001	0.02	0.126	NA	0.592
EGFR	0.005	0.854	0.011	0.489	0.094	0.546	0.592	NA
mutation

ISSN: 1756-9966